Analysts think CRDF stock price could increase by 259%
Mar 11, 2025, 11:25 AM
-32.33%
What does CRDF do
Cardiff Oncology, based in San Diego, develops drugs targeting mitosis for cancer treatment, focusing on PLK1 inhibition. Its lead candidate, Onvansertib, is undergoing five clinical trials for various cancers.
6 analysts think CRDF stock price will increase by 259.06%. The current median analyst target is $13.77 compared to a current stock price of $3.83. The lowest analysts target is $10.10 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
